Abstract Background Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials. which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM. who underwent vaccination from 12/17/2020 to 3/18/2021. https://www.diegojavierfares.com/special-offer-Turtle-Beach-Velocity-One-Flight-Simulator-Yoke-and-Throttle-Xbox-Series-X-S-One-PC-limited-choice/